









市场行情
/
股票
/
nasdaq-roiv
/

Roivant Sciences Ltd

ROIV

22.410USD

+0.620+2.85%

收盘 12/19, 16:00（美东）报价延迟15分钟

15.46B总市值

亏损市盈率 TTM



Roivant Sciences Ltd

22.410

+0.620+2.85%

概览公司财务分析

概览

公司

财务

分析

关于 Roivant Sciences Ltd 公司

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Roivant Sciences Ltd简介



公司代码ROIV

公司名称Roivant Sciences Ltd

上市日期Dec 03, 2020

CEOVenker (Eric)

员工数量750

证券类型Ordinary Share

年结日Dec 03

公司地址7Th Floor, 50 Broadway

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编SW1H 0DB

电话4412955950

网址http://roivant.com/

公司代码ROIV

上市日期Dec 03, 2020

CEOVenker (Eric)

Roivant Sciences Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Frank M. Torti, M.D.

President and Vant Chairman

13.74M

Dr. Keith S. Manchester, M.D.

Independent Director

1.93M

+0.76%

Dr. Eric Venker, M.D.

President and Immunovant Chief Executive Officer

1.34M

-0.52%

Mr. Richard Pulik

Chief Financial Officer

186.45K

-0.66%

Ms. Jennifer Humes

Chief Accounting Officer

112.25K

Mr. Ilan Oren

Independent Chairman of the Board

99.80K

+1.24%

Mr. James C. (Jim) Momtazee

Independent Director

92.14K

+0.69%

Mr. Matthew Gline

Chief Executive Officer, Director

82.26K

+4.20%

Ms. Melissa B. Epperly

Independent Director

40.50K

+2.68%

Mr. Daniel Gold

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Frank M. Torti, M.D.

President and Vant Chairman

13.74M

Dr. Keith S. Manchester, M.D.

Independent Director

1.93M

+0.76%

Dr. Eric Venker, M.D.

President and Immunovant Chief Executive Officer

1.34M

-0.52%

Mr. Richard Pulik

Chief Financial Officer

186.45K

-0.66%

Ms. Jennifer Humes

Chief Accounting Officer

112.25K

Mr. Ilan Oren

Independent Chairman of the Board

99.80K

+1.24%

收入明细

FY2025Q1

业务USD

名称

营收

占比

VTAMA

55.13M

0.00%

地区USD

名称

营收

占比

United States

55.13M

0.00%

业务

地区

业务USD

名称

营收

占比

VTAMA

55.13M

0.00%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Dexcel Pharma Technologies, Ltd.

14.79%

Fidelity Management & Research Company LLC

8.73%

Ramaswamy (Vivek)

6.77%

Morgan Stanley Investment Management Inc. (US)

5.85%

SB Investment Advisers (UK) Limited

5.80%

其他

58.07%

持股股东

占比

Dexcel Pharma Technologies, Ltd.

14.79%

Fidelity Management & Research Company LLC

8.73%

Ramaswamy (Vivek)

6.77%

Morgan Stanley Investment Management Inc. (US)

5.85%

SB Investment Advisers (UK) Limited

5.80%

其他

58.07%

股东类型

持股股东

占比

Investment Advisor

27.37%

Investment Advisor/Hedge Fund

19.48%

Hedge Fund

15.22%

Corporation

14.79%

Individual Investor

10.61%

Private Equity

9.04%

Research Firm

1.64%

Pension Fund

0.51%

Venture Capital

0.46%

其他

0.88%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

690

526.70M

77.13%

-109.19M

2025Q2

673

776.63M

112.42%

-147.35M

2025Q1

676

776.88M

113.63%

-136.03M

2024Q4

645

780.70M

109.07%

-147.12M

2024Q3

601

789.51M

107.30%

-83.47M

2024Q2

564

721.13M

95.89%

-110.95M

2024Q1

518

776.24M

96.43%

-47.46M

2023Q4

449

787.20M

97.95%

-13.44M

2023Q3

421

794.31M

100.15%

+12.61M

2023Q2

394

761.99M

100.91%

+10.72M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Dexcel Pharma Technologies, Ltd.

102.85M

15.06%

Jul 01, 2025

Fidelity Management & Research Company LLC

55.50M

8.13%

+3.83M

+7.41%

Jun 30, 2025

Ramaswamy (Vivek)

48.92M

7.16%

-1.78M

-3.50%

Sep 05, 2025

Morgan Stanley Investment Management Inc. (US)

33.37M

4.89%

+2.37M

+7.64%

Jun 30, 2025

SB Investment Advisers (UK) Limited

59.95M

8.78%

-1.90M

-3.07%

Jun 30, 2025

The Vanguard Group, Inc.

39.25M

5.75%

-1.44M

-3.53%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

35.53M

5.2%

-1.48M

-4.00%

Jun 30, 2025

QVT Financial LP

29.38M

4.3%

-36.41M

-55.34%

Jun 30, 2025

Viking Global Investors LP

34.24M

5.01%

-11.78M

-25.59%

Jun 30, 2025

Rubric Capital Management LP

20.37M

2.98%

+2.60M

+14.65%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco S&P MidCap 400 Pure Growth ETF

3.56%

Adaptiv Select ETF

2.91%

Virtus LifeSci Biotech Products ETF

2.79%

State Street SPDR S&P Biotech ETF

2.67%

WisdomTree US Value Fund

2.3%

ProShares Ultra Nasdaq Biotechnology

1.73%

Goldman Sachs Future Health Care Equity ETF

1.73%

Direxion Daily S&P Biotech Bull 3X Shares

1.41%

Invesco Nasdaq Biotechnology ETF

1.33%

WisdomTree BioRevolution Fund

1.3%

Invesco S&P MidCap 400 Pure Growth ETF

占比3.56%

Adaptiv Select ETF

占比2.91%

Virtus LifeSci Biotech Products ETF

占比2.79%

State Street SPDR S&P Biotech ETF

占比2.67%

WisdomTree US Value Fund

占比2.3%

ProShares Ultra Nasdaq Biotechnology

占比1.73%

Goldman Sachs Future Health Care Equity ETF

占比1.73%

Direxion Daily S&P Biotech Bull 3X Shares

占比1.41%

Invesco Nasdaq Biotechnology ETF

占比1.33%

WisdomTree BioRevolution Fund

占比1.3%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Roivant Sciences Ltd的前五大股东是谁？



Roivant Sciences Ltd 的前五大股东如下：
Dexcel Pharma Technologies, Ltd.持有股份：102.85M，占总股份比例：15.06%。
Fidelity Management & Research Company LLC持有股份：55.50M，占总股份比例：8.13%。
Ramaswamy (Vivek)持有股份：48.92M，占总股份比例：7.16%。
Morgan Stanley Investment Management Inc. (US)持有股份：33.37M，占总股份比例：4.89%。
SB Investment Advisers (UK) Limited持有股份：59.95M，占总股份比例：8.78%。